This was a randomized, double-blind clinical trial involving subjects with prolonged prior experience with zdv or dii monotherapy. Eligible subjects were participants in actg 175 who remained on their initially assigned monotherapy until the end of follow-up in actg 175 (data collection closed on Feb 28, 1995) and for any intervening period until entry into this study. This clinical trial comprised two sub-groups. One for subjects who were assigned zdv monotherapy in actg 175; these subjects were randomized to receive either d4t monotherapy or the combination of 3tc and zdv in a blinded manner. The other was for subjects who were assigned dii monotherapy in actg 175; these subjects were randomized to receive either the combination of dii and zdv or the combination of 3tc and zdv in a blinded manner. The primary outcome measure was change in HIV RNA copy number. The duration of study treatment was planned to be 48 weeks.
Showing the most recent 10 out of 1065 publications